Table 1.
Multivariate Cox proportional hazard regression analysis for MACCE per sortilin quartiles
| n/N (%) | Incidence* | Model 1 | Model 2 | Model 3 | Model 4 | |
|---|---|---|---|---|---|---|
| Per SD (17.6 ng/ml) | 1.58 (1.24 – 2.01)b | 1.64 (1.28 – 2.10)b | 1.67 (1.29 – 2.16)b | 1.70 (1.30 – 2.20)b | ||
| Sortilin quartile | ||||||
| Quartile 1 | 12/178 (6) | 8.0 | 1.00 | 1.00 | 1.00 | 1.00 |
| Quartile 2 | 12/180 (6) | 7.4 | 1.15 (0.49 – 2.72) | 1.17 (0.50 – 2.75) | 1.37 (0.57 – 3.26) | 1.44 (0.60 – 3.46) |
| Quartile 3 | 26/187 (13) | 19.8 | 3.04 (1.46 – 6.30)a | 3.19 (1.53 – 6.65)a | 3.44 (1.64 – 7.20)a | 3.42 (1.61 – 7.25)a |
| Quartile 4 | 24/185 (14) | 20.3 | 3.23 (1.54 – 6.76)a | 3.41 (1.62 – 7.19)a | 3.64 (1.71 – 7.76)b | 3.82 (1.77 – 8.26)b |
| Sortilin ≥ vs <median | ||||||
| ≤71 ng/ml | 24/358 (6) | 7.8 | 1.00 | 1.00 | 1.00 | 1.00 |
| >71 ng/ml | 50/372 (13) | 20.0 | 2.90 (1.74 – 4.84)b | 3.05 (1.82 – 5.10)b | 3.03 (1.80 – 5.09)b | 3.00 (1.77 – 5.08)b |
| Sortilin – threshold obtained by the ROC curve | ||||||
| ≤76 ng/ml | 33/466 (6) | 7.9 | 1.00 | 1.00 | 1.00 | 1.00 |
| >76 ng/ml | 41/264 (15) | 21.4 | 2.77 (1.72 – 4.45)b | 2.96 (1.83 – 4.79)b | 3.01 (1.84 – 4.92)b | 3.08 (1.89 – 5.03)b |
p<0.005,
p<0.001;
number of events per 1000 person-years.
Quartile 1, <60 ng/mL; Quartile 2, 60–71 ng/mL; Quartile 3, >71–84 ng/mL; Quartile 4, >84–125 ng/mL.
MACCE is defined as composite of cardiovascular death, non-fatal ST-elevation or non-ST-elevation myocardial infarction, unstable angina, and non-fatal stroke.
Model 1 is adjusted for age, fat mass.
Model 2, adjusted for age, fat mass, smoking (current, former, never), alcohol intake and physical activity.
Model 3, adjusted for age and model 2 variables plus health status (self-reported pharmacologically treated diabetes mellitus, systolic blood pressure, AAC) and medications (vitamin K antagonist, angiotensin-converting enzyme inhibitors, diuretics, fibrates).
Model 4, adjusted for age and model 3 variables plus biological measurements (testosterone, osteoprotegerin, LDL-C, C-reactive protein).